Mallinckrodt gets NDA for pain med approved; BIND Therapeutics begins lung cancer drug trial;

@FierceBiotech: ICYMI: Scripps spinout aTyr grabs $59M in venture deals with a public twist. Story | Follow @FierceBiotech

@RyanMFierce: Add Five Prime to the biotech IPO queue, hunting for $60M public debut with backers from Pfizer, GlaxoSmithKline. Report | Follow @RyanMFierce

@EmilyMFierce: FDA notes 'technical deficiencies' in Chelsea's drug filing. Article | Follow @EmilyMFierce

> The FDA has accepted a New Drug Application from Mallinckrodt ($MNK) for MNK-795, a controlled-release oral drug combo of oxycodone and acetaminophen to treat moderate to severe acute pain. Mallinckrodt uses Depomed's Acuform drug delivery technology. Release

> BIND Therapeutics has begun a Phase II clinical study of BIND-014, a therapy to treat patients with non-small cell lung cancer. Release

Medical Device News

@FierceMedDev: Check out last week's special report: Top 10 Med Tech Investments of Q2. Report | Follow @FierceMedDev

@MarkHFierce: ReVision optics closed $55M in new equity financing. Medical Device financing shows some signs of life. Release | Follow @MarkHFierce

@DamianFierce: Quintiles has signed up to help Ascendancy Healthcare cash in on the Chinese pharma boom. More | Follow @DamianFierce

 @MichaelGFierce: NeuroSigma to begin PhIII epilepsy device trial. Item | Follow @MichaelGFierce

> Siemens sacking CEO as bad bets raid revenue. Report

> Glass implant envisioned to promote leg, arm bone repairs. More

> J&J leads ReVision Optics' $55M financing round. Story

Pharma News

@FiercePharma: Pfizer to split operations three ways. Story | Follow @FiercePharma

@EricPFierce: EU doesn't like smell of Germany's exemption to financially struggling drugmakers from paying drug rebates. More | Follow @EricPFierce

@CarlyHFierce: 's former head of China biz will be returning to China to assist with bribery probe. 18 more reportedly detained there. Article | Follow @CarlyHFierce

> Valeant to fire thousands, restructure ops after Bausch buyout. Report

> U.S. court upturns Teva's patents on cash-cow Copaxone. News

> OTC specialist Perrigo nabs Elan and its tax rate for $8.6B. Article

CRO News

> Swiss CRO Psi reaches into South Africa. Item

> Quintiles teams up with Ascendancy in China. News

> Icon ticks up guidance as revenue leaps another 21%. Report

> CRA buys Comprehensive Clinical's late-phase biz. Article

> AMRI working to get out from under FDA warning. More

Biotech IT News

> Medidata shares soar on another record quarter in Q2. Item

> AstraZeneca adds software from Dotmatics to virtual neuroscience group. Article

> Novo Nordisk among latest to join pharma flock on Twitter. Story

> Sanofi returns to the crowdsourcing well for diabetes app. More

> NIH earmarks $96M for multiyear effort to maximize value of Big Data. Report

And Finally... New research suggests that it may be possible for people to recover from autism. Story

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.